Search PubMed⌕ Search

Biomedical subjects

L Norton

Publications and source records attributed to L Norton.

230 records · Page 13Linked to original sources
PubMedDate not supplied

A pilot study of interpersonal psychotherapy by telephone with cancer patients and their partners.

A single-arm pilot study explored the feasibility of adapting in Interpersonal Psychotherapy (IPT) by telephone to reduce psychological distress and to enhance coping during cancer treatment. Therapy focuses on role transitions, interpersonal conflicts, and grief precipitated by cancer. Breast cancer patients receiving high-dose chemotherapy received weekly sessions with a psychologist throughout chemotherapy and for 1 month afterwards. Patients could invite one 'partner' to receive individual telephone IPT. Psychosocial functioning was assessed using standardized measures at study entry, after chemotherapy, and following telephone IPT. Accrual and participation supplied evidence of feasibility: 14 patients and 10 partners were recruited, 82.5% of those eligible. Patients had a mean of 16 sessions; partners had a mean of 11. Participants rated their satisfaction with the program between 'good' and 'excellent'. A test of the efficacy of telephone IPT requires a larger, randomized trial. In order to standardize the intervention, a treatment manual was developed. This study indicated the importance of outreach to family members as well as to cancer patients, intensive patient education about oncology treatment and the medical care setting, and psychosocial services that continue after cancer treatment has been completed.

Adaptation, Psychological↗
PubMedDate not supplied

Adjuvant systemic therapy for early breast cancer.

Systemic therapy (chemotherapy or hormonal therapy) as an adjuvant to modalities of local control is now an integral part of the management of almost all patients with primary breast cancer metastatic to axillary lymph nodes. In addition, recent data suggest an expanding role for such treatments in patients without axillary involvement. Although some node-negative patients should probably not receive adjuvant therapy, the precise criteria to be used for selection are still under active discussion in the literature. Of the two types of systemic treatment, it is generally accepted that chemotherapy is indicated for premenopausal patients and that tamoxifen is useful for postmenopausal patients whose tumors contain estrogen or progesterone receptors. The recent analysis of several studies has suggested that chemotherapy may add to the benefits of tamoxifen in some postmenopausal patients as well. A possible role for tamoxifen in younger patients is being evaluated. For patients at relatively low risk of systemic relapse (i.e., those with zero to three involved axillary lymph nodes), no chemotherapy regimen has yet shown an advantage over 6 months of cyclophosphamide, methotrexate and 5-fluorouracil. For patients at high risk, however, doxorubicin-based regimens have demonstrated benefits. High-dose chemotherapies, some involving autologous bone marrow support, are being investigated for patients with ten or more involved nodes who are at very high risk of the eventual development of stage IV disease.

Antineoplastic Combined Chemotherapy Protocols↗
PubMedDate not supplied

Chemotherapy for urothelial tract malignancies: breaking the deadlock.

Chemotherapy treatments for urothelial tract tumors have improved to the point that some patients are enjoying long-term disease-free survival. Moreover, with currently available agents and combinations, and with our increased application of clinical and biologic prognostic factors, we are refining our ability to select appropriate therapies for individual patients. We have learned that once the decision is made to use combination chemotherapy, adequate doses should be used. This can be facilitated by the coadministration of hematopoeitic growth factors. Recently completed phase II trials have confirmed that higher doses and dose rates may increase response proportions of and in particular, the proportion of complete responses. The finding that granulocyte colony stimulating factor enhances the sensitivity of tumor cells to methotrexate in vitro and to other agents studied against urothelial tumors implanted in nude mice implies an expanded role for these compounds. However, because non-hematologic toxicities are still important, it is unlikely that simple escalation of all components a four drug regimen such as of M-VAC (cisplatin, methotrexate, vinblastine, and doxorubicin) will have a significant impact on survival. In addition, as more is learned about the pharmacokinetic and pharmacodynamic relationships of the active agents, it appears that better schedules can be designed to improve the therapeutic index of the compounds. Ultimately we will be able to determine drug sensitivities, both at the start of therapy and as it evolves during treatment, that will allow a better selection of a particular chemotherapeutic regimen. For example, mdr1 induction appears to play a significant role in the therapy for treatment-resistant tumors. The availability of a number of active salvage regimens that are not constrained by this mechanism hints that changes in drug sequencing and drug scheduling may provide a significant improvement in outcome. While established combination chemotherapy regimens should be considered standard therapy in appropriately selected patients, promising strategies and new agents need to be investigated if we are to "break the deadlock" that has appeared in the treatment of urothelial tumors. These investigations can be performed safely in a well-controlled fashion to enable the identification of new regimens and to compare promising strategies with appropriate control populations in randomized trials.

Antineoplastic Combined Chemotherapy Protocols↗
PubMedDate not supplied

Endoscopic versus operative gastrostomy: final results of a prospective randomized trial.

This study compared operative gastrostomy (OG) (by surgeons) with endoscopic gastrostomy (PEG) (by physicians) in a prospective randomized fashion to determine whether one technique was superior. PEG (Sachs-Vine) and OG (Stamm) were done using local anesthesia. Patients were assessed for complications, mortality, tube function, and cost. Groups were equally matched for indications and underlying disease. Fifty-seven had OG and 64 had attempted PEG. Complications occurred in 26% of OG patients and 9% died. Complications occurred in 25% of PEG patients and 12% died. Tube feeding was initiated in both groups within a mean of 29 (24 to 72) hours of the gastrostomy placement. OG cost $1675 and PEG $979 to perform. Twenty-one PEG patients required endoscopic tube change which raised their total cost to $1574. We conclude there is no difference between OG (using local anesthesia) and PEG with regard to morbidity, mortality, or tube function. The endoscopic technique does appear to have economic advantage.

Adolescent↗
PubMedDate not supplied

An experimental analysis of classically conditioned nausea during cancer chemotherapy.

This study investigated classical conditioning in women undergoing outpatient adjuvant chemotherapy for breast cancer. Breast cancer chemotherapy outpatients were randomly assigned either to an Experimental Group (exposed to a distinctive stimulus before each infusion of chemotherapy) or to a Control Group. After repeated infusions of chemotherapy, patients' responses to the experimental stimulus were assessed in a location not associated with chemotherapy. Experimental Group patients had increased nausea (self-reported on a visual analog scale) following the presentation of the experimental stimulus at this test trial, whereas Control Group patients did not. Two other measures of nausea corroborated these results. Post hoc statistical analyses confirmed predictions based on conditioning theory. This conditioning model of anticipatory nausea bears witness to the relevance of classical conditioning in clinical medicine.

Antineoplastic Combined Chemotherapy Protocols↗
PubMedDate not supplied

Pharmacokinetic profile of flunarizine after single and multiple dosing in epileptic patients receiving comedication.

This preliminary clinical study describes the pharmacokinetic characteristics of flunarizine (FLN) following single and multiple dosing in epileptic patients receiving comedication. Three groups [phenytoin (PHT) only, carbamazepine (CBZ) only, and PHT plus CBZ] of four patients each were studied. Large interindividual differences, but no statistically significant differences in pharmacokinetic parameters, were observed between the three groups. Following a single dose, mean values (and ranges) for apparent clearance, volume distribution, and elimination half-life (t1/2) were 0.504 L/h/kg (0.086-1.119), 12,431 L (1,959-20,920), and 308 h (61-506), respectively. FLN had no effect on PHT or CBZ steady-state levels but PHT or CBZ appeared to induce the metabolic disposition of FLN. The effect of dose on FLN kinetics could not be evaluated in this preliminary study.

Adult↗
PubMedDate not supplied

Metastatic hypernephroma to the head and neck.

Eight cases of metastatic hypernephroma to the head and neck are presented with CT documentation. Hypernephroma is the third most common infraclavicular tumor to metastasize to the head and neck. Such metastases occur in about 15% of patients with this neoplasm, and nearly 8% of patients with this tumor present with disease in the head and neck region. These metastases are usually vascular and may either clinically precede the diagnosis of the renal primary tumor or may occur many years after apparently successful surgery of the primary tumor. These unusual patterns of behavior are reviewed. One of the cases presented here is the first reported incidence of cervical lymph node metastasis with hemorrhage to be documented by CT, thus adding this entity to the list of imaging differential diagnoses of cystic-appearing neck masses.

Angiography↗
PubMedDate not supplied

[Kinetics of breast neoplasms].

Breast cancer is a disease moderately responsive to chemotherapy. While its curability is inversely related to the tumor burden, a relevant number of patients still progress to metastatic disease even after adjuvant chemotherapy. Also, high-dose chemotherapy appears promising, but can not yet be considered ultimately curative of breast cancer. Different variables, biological, kinetic and treatment-related, account for the clinical behaviour of this disease. In order to improve its curability, they will all need to be taken into account in planning future treatment strategies. One of the most effective ways to understand and predict the clinical behaviour of breast cancer is the development of appropriate mathematical models explaining its growth-patterns. Aim of this paper is to review the two fundamental models, the exponential and the Gompertzian. The exponential model is at the basis of the Skipper-Schabel and the Goldie-Coldman hypotheses, while the Norton-Simon hypothesis has been formulated from the gompertzian model. The latter appears to better fit the vast amount of clinical data which are presently available: from Bloom's analysis of untreated breast cancer patients, to the results of large clinical trials, to the data emerged from the recent meta-analysis. Characteristic of a gompertzian growth pattern is that exponential growth is matched by exponential retardation of growth. In 1943 Delbruck and Luria demonstrated that random mutations could account for the development of virus resistance in bacteria and were able to estimate the rate of mutation as a function of the growth rate of bacteria. Shortly after Law demonstrated that resistance to methotrexate in murine leukemia occurred similarly. The concept of combination chemotherapy actually derived from the idea that cancer cells could be resistant to chemotherapy even before exposure to it. Goldie and Coldman applied the Delbruck/Luria model to hypothesize the use of non cross-resistant alternating combination chemotherapy as a better way to eliminate the risk of resistance. They also suggested that many different drugs were to be used as soon as possible, when the tumor size is still small. Most of their predictions were based on the Skipper/Schabel model of the exponential growth of cancer and on its deriving log-kill model. A large amount of clinical data are now suggesting that the behaviour of breast cancer is best described by gompertzian growth: in particular, gompertzian growth is a tenable model of breast cancer growth for both the unperturbed and the perturbed (by treatment) states.(ABSTRACT TRUNCATED AT 400 WORDS)

Breast Neoplasms↗
PubMedDate not supplied

The impact of the sequence of radiation and chemotherapy on local control after breast-conserving surgery.

PURPOSE: We conducted this study to evaluate the effects of delaying primary radiation after adjuvant chemotherapy on local control following breast-conserving surgery compared with radiation delivered immediately following surgery. PATIENTS AND METHODS: This retrospective, nonrandomized study evaluated local control in 471 patients treated with breast-conserving surgery and radiation from 1980 through 1990. Three patient subsets were studied, identified by the sequence of radiation and adjuvant therapy if given. The three subgroups were: surgery, radiation, no chemohormonal therapy (332 patients; RT only); surgery, all chemotherapy, radiation (53 patients; chemo first); and surgery, chemotherapy, radiation, chemotherapy (86 patients; sandwich). Median follow-up times ranged from 53 months in the chemo first group to 77 months in the RT only group. RESULTS: All three groups had similar local control rates at 3 and 5 years. At 36 months, the actuarial local control rate achieved by the RT only group was 98% (confidence interval: 95%-99%); by the chemo first group, 94% (CI: 82%-98%); and the sandwich group, 96% (CI: 89%-99%). At 60 months, the local control rate for the RT only group was 96% (CI: 93%-98%), the chemo first group, 86% (CI: 70%-94%) and the sandwich group 95% (CI: 87%-98%). CONCLUSIONS: This report demonstrates no significant difference in the local recurrence rate following breast-conserving surgery and radiation therapy, whether radiation immediately followed the surgery or whether it was delayed by the administration of postsurgical adjuvant chemotherapy. These data differ from other reports, and suggest that this question remains open, requiring further follow-up that focuses not only on local control as an endpoint, but disease-free and overall survival as well.

Antineoplastic Combined Chemotherapy Protocols↗